PARP inhibitors
20 Jul 2010
PARP inhibitors
Targeted therapy in sarcoma treatment
Current techniques in the treatment of lung cancer
ALK inhibitor shows high response rate in patients with advanced NSCLC harboring a specific gene alteration
The role of genetic mutations in lung cancer
The use of monoclonal antibodies to treat mesothelioma
The use of targeted radiotherapy to treat lung cancer
Asbestos related diseases
The future of lung cancer treatment
Advances in the treatment of lung cancer
Stem cells in breast cancer
Individualisation and personalisation of colorectal cancer treatments